Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) EBITDA (2024 - 2025)

Maze Therapeutics has reported EBITDA over the past 2 years, most recently at -$38.1 million for Q4 2025.

  • Quarterly EBITDA fell 28.03% to -$38.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$142.9 million through Dec 2025, down 348.15% year-over-year, with the annual reading at -$142.9 million for FY2025, 348.15% down from the prior year.
  • EBITDA was -$38.1 million for Q4 2025 at Maze Therapeutics, down from -$33.0 million in the prior quarter.
  • Over five years, EBITDA peaked at $139.6 million in Q2 2024 and troughed at -$38.1 million in Q4 2025.